RxDoctor Payments Data

Stephanie McMellon, APRN

Clinical Nurse Specialist · Jonesboro, ARNPI 1033511449

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $199 and has fallen 55.5% since, to $89 in 2025.

$506in general payments, 2019–2025

Across 20 payments — averaging $25.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$103
  • Novartis$94
  • Boston Scientific$81
  • Johnson & Johnson$68
  • Inspire Medical Systems, Inc.$46
  • Angiodynamics, Inc.$31
  • plus $83 from 5 others

What the payments were for

  • Food & beverage$506100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few clinical nurse specialist providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$87,358
Medicare patients
824
Services billed
1,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban268$191,642
EntrestoSacubitril/Valsartan125$85,639
JardianceEmpagliflozin81$49,007
XareltoRivaroxaban72$41,801
Repatha SureclickEvolocumab27$34,776
FarxigaDapagliflozin Propanediol44$29,173
VascepaIcosapent Ethyl13$5,122
Atorvastatin Calcium469$3,192
Metoprolol Succinate251$1,956
Ezetimibe211$1,913
Ranolazine ErRanolazine51$1,783
Carvedilol334$1,571
Hydralazine Hcl215$1,477
FenofibrateFenofibrate Nanocrystallized111$1,410
ClopidogrelClopidogrel Bisulfate161$1,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$191,642268 claims
NovartisEntresto$94$85,639125 claims
Johnson & JohnsonXarelto$68$41,80172 claims
AstraZenecaFarxiga$103$29,17344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical nurse specialist providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other clinical nurse specialist in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →